Selective serotonin reuptake inhibitors anti-depressants act as endocrine disruptors of the feto-placental unit
Andrée-Anne Hudon Thibeault, J Thomas Sanderson and Cathy Vaillancourt
INRS, Canada

Abstract

Selective serotonin-reuptake inhibitors (SSRIs) are prescribed to up to 6.2% of pregnant women. SSRIs have been associated with adverse effects on pregnancy and fetal development. However, the action of SSRIs on the endocrine function of the feto-placental unit has not been studied. Our objective was to characterize the effect of fluoxetine, the most commonly prescribed SSRI during pregnancy, and its active metabolite, norfluoxetine, on placental aromatase (CYP19) and feto-placental steroidogenesis. A co-culture of BeWo (human villous trophoblast-like) and H295R (human fetal-like adrenocortical) cells, which we established as a representative model of feto-placental steroidogenesis, was treated with physiologically relevant concentrations (0.3, 1 and 3 μM) of fluoxetine or norfluoxetine for 24 h. Fluoxetine did not affect β-human chorionic gonadotropin, progesterone, dehydroepiandrosterone, androstenedione, estrone, estradiol or estriol production. Norfluoxetine concentration-dependently reduced the production of estrone up to 62% and estradiol by 70% at 3 μM. In BeWo cells, fluoxetine induced CYP19 activity by 1.6- and 2.3-fold at 1 and 3 μM, respectively, whereas norfluoxetine decreased it by 54% at 3 μM. In H295R cells, fluoxetine (1 μM) and norfluoxetine (3 μM) increased CYP19 activity 1.3 and 1.4-fold, respectively. The effect of citalopram, sertraline, paroxetine and venlafaxine on CYP19 activity in BeWo cells was also determined. Paroxetine induced CYP19 activity by 1.7- and 1.9-fold at 1 and 3 μM, respectively; sertraline by 2.7-fold at 1 μM; venlafaxine and citalopram had no effect. Our results indicate that SSRIs may disrupt estrogen biosynthesis in the feto-placental unit, which could have adverse effects on pregnancy and fetal development.

Biography

Pr. Vaillancourt obtained her M.Sc. and Ph.D. degrees in Endocrinology from the University of Montreal (Canada) followed by postdoctoral studies in Psychiatry at the McGill University (Canada), and in Neurosciences at the University of Reading (UK). She is a placentologist. Over the past ten years, her research program funded by NSERC-discovery grant has allowed demonstrating a crucial role of melatonin and its receptors in placental function. Her group has shown that melatonin is highly produced in the placenta where it protects against molecular damage and cellular dysfunction arising from oxidative stress playing a protective role in pregnancy and fetal development.